B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRK4

MOLECULAR TARGET

G protein-coupled receptor kinase 4

UniProt: P32298NCBI Gene: 286820 compounds

GRK4 (G protein-coupled receptor kinase 4) is targeted by 20 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRK4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1erlotinib5.55256
2tozasertib4.3375
3ruxolitinib4.2368
4bosutinib4.0858
5midostaurin3.8546
6nintedanib3.6136
7tae 6843.4330
8fedratinib3.4029
9dovitinib3.0921
10lestaurtinib3.0420
11ruboxistaurin2.9418
12r 4062.8316
13pha 6657522.7114
14kw 24492.6413
15gsk 4613642.4010
16balanol2.309
17su 0148132.208
18tg100 1152.087
19Axitinib0.691
20Crizotinib0.691

About GRK4 as a Drug Target

GRK4 (G protein-coupled receptor kinase 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 20 compounds with documented GRK4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRK4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.